<DOC>
	<DOC>NCT02047422</DOC>
	<brief_summary>To compare the effectiveness and safety of diuretics add-on strategy in chronic heart failure patients</brief_summary>
	<brief_title>A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Metolazone</mesh_term>
	<criteria>1. dyspnea at rest or minimal activity 2. tachypnea (respiratory rate &gt; 20/min) or rales or pulmonary edema on chest Xray 1. hospitalization for acute heart failure decompensation 2. cardiogenic shock (Systolic Blood Pressure &lt; 80mmHg) 3. Need or plan for renal replacement therapy (dialysis, kidney transplant) 4. serum creatine level &gt; 2.5mg/dl 5. serum potassium (K+) &gt; 5.5mg/dl 6. Age &gt; 80 years old or poor compliance patients 7. allergy, adverse drug reaction, hypersensitivity to any kinds of diuretics 8. life expectancy &lt; 6 months (e.g. metastatic malignancy, liver cirrhosis) 9. pregnancy or women at age of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Heart failure, diuretics, kidney, glomerular filtration rate</keyword>
</DOC>